FDA warns Take­da over asep­tic pro­cess­ing, in­ad­e­quate in­ves­ti­ga­tions

The FDA last week warned Japan­ese drug­mak­er Take­da over good man­u­fac­tur­ing prac­tice (GMP) vi­o­la­tions ob­served dur­ing an in­spec­tion of its Hikari, Ya­m­aguchi fa­cil­i­ty last No­vem­ber …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER